Year-end Sale % OFF 
Abstract
Introduction. Hepatocellular carcinoma is a serious problem for patients with hemophilia. Hepatitis C virus infection is the most common comorbidity in adult patients with inherited bleeding disorders, including hemophilia. Case Report. This is a case report of a 65-year-old male patient with hemophilia A and hepatocellular carcinoma. Sorafenib treatment was initiated at a dose of 400 mg/day, after a 50% dose reduction. In order to prevent bleeding episodes, prophylactic doses of replacement plasma-derived factor VIII concentrate (40 U/kg of body weight three times a week) were introduced. Our patient received a total of ten cycles of sorafenib therapy, in good general condition, without bleeding episodes. Conclusion. Differential chemotherapy is not contraindicated in patients with inherited bleeding disorders, provided that adequate hemostasis is achieved. In such cases, a multidisciplinary approach is necessary for the management of hemophilia during systemic cancer treatment.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
